Reckitt Benckiser to pay federal government $1.4B to resolve investigation into opioid sales
The settlement, reached Thursday, resolves an investigation concerning the opioid addiction treatment Suboxone Film, made by former subsidiary Invidior.
Opioid dependence treatment from BDSI aims to challenge RB’s Suboxone
As drug abuse grows and drug addiction specialists seek new ways to treat opioid dependence, BioDelivery Sciences International (NASDAQ:BDSI) is positioning itself to enter that market as early as next year. BDSI plans to file a new drug application for its opioid dependence treatment BEMA Buprenorphine in the first half of 2013. Like current market […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BDSI’s opioid-addiction drug candidate aims to challenge market leader RB
An opioid-dependence treatment being developed by BioDelivery Sciences International (NASDAQ:BDSI) is on track for a New Drug Application filing in the second half of 2012, making it a contender to compete against current market leader Reckitt Benckiser (LSE:RB). Raleigh, North Carolina-based specialty pharmaceutical company BDSI announced positive preliminary results from a clinical trial that studied […]